Detection of novel therapies using a multi-national, multi-institutional registry of cutaneous immune-related adverse events and management.

Autor: Mital R; The Ohio State University College of Medicine, Columbus, OH, USA.; Department of Dermatology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA., Otto TS; Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.; Department of Dermatology, Massachusetts General Hospital, Boston, MA, USA., Savu A; The Ohio State University College of Medicine, Columbus, OH, USA., Baumrin E; Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA., Cardones AR; Division of Dermatology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, USA., Carlesimo M; Dermatology Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy., Caro G; Dermatology Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy., Freites-Martinez A; Department of Dermatology, Hospital Ruber de Juan Bravo, Universidad Europea, Madrid, Spain., Hirner JP; Department of Dermatology, University of Missouri Health Care, Columbia, MO, USA., Markova A; Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Cornell Medical College, New York, NY, USA., McLellan BN; Division of Dermatology, Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, New York, NY, USA., Rossi A; Dermatology Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy., Sauder MB; Princess Margaret Hospital Cancer Centre, Toronto, ON, Canada., Seminario-Vidal L; Cutaneous Oncology Department, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Sibaud V; Department of Dermatology, Institut Claudius Regaud, Institut Universitaire du Cancer Toulouse-Oncopole, Toulouse, France., Owen DH; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University James Comprehensive Cancer Center, Columbus, Ohio, USA., Dulmage BO; Department of Dermatology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA., Chen ST; Department of Dermatology, Massachusetts General Hospital, Boston, MA, USA., Kaffenberger BH; Department of Dermatology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
Jazyk: angličtina
Zdroj: International journal of dermatology [Int J Dermatol] 2023 Aug; Vol. 62 (8), pp. 1020-1025. Date of Electronic Publication: 2023 May 19.
DOI: 10.1111/ijd.16714
Abstrakt: Background: Cutaneous immune-related adverse events (cirAEs) remain a prevalent and common sequelae of immune checkpoint inhibitor (ICI) therapy, often necessitating treatment interruption and prolonged immune suppression. Treatment algorithms are still poorly defined, based on single-institution case reports without adequate safety assessments, and subject to publication bias.
Methods: Data in this registry were collected through a standardized REDCap form distributed to dermatologists via email listserv.
Results: Ninety-seven cirAEs were reported from 13 institutions in this registry. Topical and systemic steroids were the most common treatments used; however, targeted treatment matched to disease morphology was identified at numerous sites. Novel cirAE therapy uses that to our knowledge have not been previously described were captured including tacrolimus for the treatment of follicular, bullous, and eczematous eruptions and phototherapy for eczematous eruptions. Moreover, further evidence of cirAE treatment applications sparsely described in literature were also captured in this study including dupilumab and rituximab for bullous eruptions, phototherapy for lichenoid and psoriasiform eruptions, and acitretin for psoriasiform eruptions, among others. No serious adverse events were reported. Numerous targeted therapeutics including dupilumab, rituximab, and psoriasis biologics, among others, were associated with a cirAE grade improvement of ≥2 grades in every patient treated.
Conclusion: This study suggests that a multi-institutional registry of cirAEs and management is not only feasible but that the information collected can be used to detect, evaluate, and rigorously assess targeted treatments for cirAEs. Further expansion and modification to include treatment progression may allow for sufficient data for specific treatment recommendations to be made.
(© 2023 The Authors. International Journal of Dermatology published by Wiley Periodicals LLC on behalf of the International Society of Dermatology.)
Databáze: MEDLINE
Externí odkaz: